BioCentury
ARTICLE | Product Development

Triple's shot

ASCO 2016: How triple-negative breast cancer landscape is evolving

June 13, 2016 7:00 AM UTC

After years of disappointments in the search for better treatments for triple-negative breast cancer, a handful of abstracts presented at the American Society of Clinical Oncology meeting could signal a sea change for this difficult-to-treat breast cancer subtype.

For the first time, several companies have reported data for targeted therapies that substantially bested the 15-20% response rates historically seen with chemotherapies. In addition, evidence is accumulating around new markers that could redefine some portion of triple-negative breast cancer (TNBC), currently a catch-all that is defined by the lack of receptor targets that marketed drugs inhibit: estrogen receptor (ER), progesterone receptor (PR) and HER2...